Generic User Fees Might Combine Inspection Visits, Boost Foreign Cooperation
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency outlines ideas for coordinating and combining different types of facility inspections in generic drug user fee negotiations, while industry asks how it will affect collaboration with international regulators.
You may also be interested in...
Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations
FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.
Collaboration On Foreign Inspections Helps FDA Improve Resource Allocations
FDA better allocated resources for foreign inspections based on information European and Australian authorities shared in a two-year pilot program, including conducting good manufacturing practices inspections that met the needs of multiple agencies.
GMP Oversight Collaboration Helps FDA Plan, But Not Avoid, Foreign Inspections
FDA has improved planning efforts with information borrowed from European and Australian authorities, but an inspection collaboration between the three countries could not help it avoid some inspections.